Nyxoah SA (NYXH)
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Specialties
Nyxoah S.A.
NASDAQ:NYXHHealthcare · Medical - Specialties
-1.85%$0.8715
AH$0.8715+0.00%vs close
Mkt Cap$87.21M
Float75.94M
O/S100.07M
Vol
$ Vol
RVOL
Inst Own22.6%
SI0.3%
Earnings
Dilution
| Form | Description | Links | |
|---|---|---|---|
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 13G/A | |||
| 6-K | |||
| 6-K | |||
| 13G/A | |||
| 6-K | |||
| 13G | |||
| 6-K | |||
| 13D/A | |||
| 6-K | |||
| 424B5 | |||
| FWP | |||
| 6-K | |||
| 424B5 | |||
| 6-K | |||
| S-8 | |||
| 20-F | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 13G | |||
| 6-K | |||
| 6-K |
1-25 of 178 filings
…
Recent SEC filings with analysis
- 6-KNyxoah reported preliminary Q3 2026 global net revenue of approximately €9.2 million, up 19% sequentially, with U.S.
- 6-KNyxoah SA (Nasdaq/Euronext Brussels: NYXH) announced on September 28, 2026 the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026,…
- 6-KNyxoah SA announced that CFO John Landry will step down effective October 2, 2026, to pursue another professional opportunity.